Bone status after cessation of use of injectable progestin contraceptives.
BACKGROUND
Women using injectable progestin contraceptives (IPCs) have lower bone mineral density than nonusers. We assessed whether bone loss is completely reversible after cessation of IPC use, whether different IPCs have different effects and whether effects vary by age at first use.


METHODS
In a cross-sectional study in Cape Town, South Africa, 3487 premenopausal black and mixed race women aged 18-44 years were interviewed for information on contraceptive history and risk factors for decreased bone mineral density, and ultrasound measurements of the left calcaneus were taken. Adjusted means of the ultrasound measures for categories of IPC use were obtained using multivariable linear regression.


RESULTS
Current users of IPCs had the lowest ultrasound measures, while the measures of women who had ceased IPC use at least 2-3 years previously were similar to or greater than those of never users of IPCs. The effects of depot medroxyprogesterone acetate and norethisterone enanthate were similar. The calcaneus measures were unrelated to age at which use began after control for confounding factors.


CONCLUSIONS
The data suggest that bone loss during IPC use is reversible and that this loss of bone is completely recovered several years after cessation of use.
Rosenberg
Lynn
L
Slone Epidemiology Center at Boston University, Boston, MA 02215-1201, USA. lrosenberg@slone.bu.edu
Zhang
Yuqing
Y
Constant
Deborah
D
Cooper
Diane
D
Kalla
Asgar A
AA
Micklesfield
Lisa
L
Hoffman
Margaret
M
D000293:Adolescent; D000328:Adult; D000554:Ambulatory Care Facilities; D044383:Black People; D015519:Bone Density / Q000187:drug effects*; D001862:Bone Resorption / Q000139:chemically induced*; D002111:Calcaneus / Q000000981:diagnostic imaging; D003271:Contraceptive Agents, Female / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D003430:Cross-Sectional Studies; D003692:Delayed-Action Preparations; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007273:Injections, Intramuscular; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D009640:Norethindrone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology; D013019:South Africa; D014463:Ultrasonography
D003271:Contraceptive Agents, Female; D003692:Delayed-Action Preparations; D017258:Medroxyprogesterone Acetate; C024319:norethindrone enanthate; D009640:Norethindrone